By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators discuss new findings in Biotechnology. According to news reporting from Brisbane, Australia, by NewsRx journalists, research stated, "Donor T cells play pivotal roles in graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects following bone marrow transplantation (BMT). DNAX accessory molecule 1 (DNAM-1) is a costimulatory and adhesion molecule, expressed mainly by natural killer cells and CD8(+) T cells at steady state to promote adhesion to ligand-expressing targets and enhance cytolysis."
The news correspondents obtained a quote from the research from Royal Brisbane Hospital, "We have analyzed the role of this pathway in GVHD and GVL. The absence of DNAM-1 on the donor graft attenuated GVHD in major histocompatibility complex (MHC)-mismatched and MHC-matched BMT following conditioning with lethal and sublethal irradiation. In contrast, DNAM-1 was not critical for GVL effects against ligand (CD155) expressing and nonexpressing leukemia. The effects on GVHD following myeloablative conditioning were independent of CD8(+) T cells and dependent on CD4(+) T cells, and specifically donor FoxP3(+) regulatory T cells (T-reg). The absence of DNAM-1 promoted the expansion and suppressive function of T-reg after BMT."
According to the news reporters, the research concluded: "These findings provide support for therapeutic DNAM-1 inhibition to promote tolerance in relevant inflammatory-based diseases characterized by T-cell activation."
For more information on this research see: Promoting regulation via the inhibition of DNAM-1 after transplantation. Blood, 2013;121(17):3511-3520. Blood can be contacted at: Amer Soc Hematology, 2021 L St NW, Suite 900, Washington, DC 20036, USA. (American Society of Hematology - www.hematology.org/; Blood - bloodjournal.hematologylibrary.org/)
Our news journalists report that additional information may be obtained by contacting M. Koyama, Royal Brisbane Hospital, Dept. of Bone Marrow Transplantat, Brisbane, Qld 4029, Australia. Additional authors for this research include R.D. Kuns, S.D. Olver, K.E. Lineburg, M. Lor, B.E. Teal, N.C. Raffelt, L. Leveque, C.J. Chan, R.J. Robb, K.A. Markey, K.A. Alexander, A. Varelias, A.D. Clouston, M.J. Smyth, K.P.A. MacDonald and G.R. Hill (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Brisbane, Leukemia Gene Therapy, Australia and New Zealand, Graft-Versus-Host Disease
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC